GlassScriptPhysician profile
William M Thompson
NPI 1174588891
$12,480.74
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,631 · 2020: $2,497 · 2021: $1,717 · 2022: $3,139 · 2023: $2,365 · 2024: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,498.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,126.12 | 2019-2023 | |
| Viiv Healthcare Company | $1,936.69 | 2019-2023 | Dovato, Cabenuva, Apretude |
| Janssen Biotech, INC. | $1,085.46 | 2019-2023 | Symtuza |
| Abbvie INC. | $1,041.47 | 2021-2023 | Dalvance, Avycaz, Teflaro |
| Emd Serono, INC. | $815.08 | 2019-2023 | Serostim |
| Insmed, INC. | $585.10 | 2019-2023 | Arikayce |
| Theratechnologies INC. | $520.39 | 2019-2023 | Trogarzo, Egrifta |
| Amgen INC. | $472.39 | 2019-2023 | Otezla, Repatha |
| Allergan, INC. | $311.03 | 2019-2020 | |
| Melinta Therapeutics, LLC | $267.30 | 2019-2022 | |
| Amarin Pharma, INC. | $214.60 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $177.80 | 2020-2023 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $176.19 | 2019-2020 | |
| Shionogi INC | $174.23 | 2022-2024 | Fetroja |
| Napo Pharmaceuticals INC | $172.25 | 2020-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $164.17 | 2019-2022 | |
| Antares Pharma, INC. | $142.33 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Smith+Nephew, INC. | $120.62 | 2019-2022 | |
| Abiomed | $119.20 | 2024 | Impella |
| Philips North America LLC | $102.11 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $100.29 | 2020 | |
| Tactile Systems Technology INC | $93.75 | 2019-2023 | Entre Plus, Flexitouch Plus |
| Vyera Pharmaceuticals, LLC | $79.76 | 2019-2022 | |
| Pfizer INC. | $78.80 | 2021-2022 | |
| Eisai INC. | $66.34 | 2020 | |
| Ferring Pharmaceuticals INC. | $66.27 | 2023 | Rebyota |
| Exact Sciences Corporation | $63.05 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $45.79 | 2020 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| Ascend Therapeutics US, LLC | $25.22 | 2021 | |
| Csl Behring | $24.81 | 2022 | |
| Aytu Biopharma, INC. | $23.96 | 2019 | |
| Ironwood Pharmaceuticals, INC | $18.06 | 2020 | |
| Janssen Scientific Affairs, LLC | $17.95 | 2019 | |
| Nabriva Therapeutics, Plc | $12.22 | 2021 | |
| Daiichi Sankyo INC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.